Company
Lumosa Therapeutics Co. Ltd
Headquarters: Taipei, Taiwan
Employees: 46
CEO: Mr. Rong-Jin Lin Ph.D.
Market Cap
TW$39.15 Billion
TWD as of Jan. 1, 2025
US$1.19 Billion
Lumosa Therapeutics Co. Ltd Categories
Taiwan Healthcare BiotechnologyTaiwan Healthcare Taiwan Biotechnology
Top Competitors by Market Capitalization
Industry: Biotechnology
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $622.07 B |
| Vertex Pharmaceuticals Incorporated | $113.24 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $76.33 B |
| Marinomed Biotech AG | $56.13 B |
Sector:
| Company | Market Cap (USD) |
|---|---|
| Lilly | $689.42 B |
| Novo Nordisk | $622.07 B |
| UnitedHealth Group | $487.54 B |
| Johnson & Johnson | $353.05 B |
| AbbVie | $301.60 B |
Detailed Description
Lumosa Therapeutics Co., Ltd., a clinical-stage pharmaceutical company, develops therapies and solutions for neurological and oncological diseases in Taiwan. The company offers LT - 1001, an analgesic injection that has completed Phase III clinical trials for severe pain relief after surgery. It is also developing LT3001, which is in Phase II clinical trial for the treatment of acute ischemic stroke; LT5001 that has completed Phase Ib clinical trial for uremic pruritus; and LT2003, which is in pre-clinical stage for the treatment of oncology. Lumosa Therapeutics Co., Ltd. was incorporated in 2000 and is based in Taipei, Taiwan.
Financials
| Last Financial Reports Date | Sept. 30, 2024 |
| Revenue TTM | TW$47.7 M |
| EBITDA | TW$-335,080,992 |
| Gross Profit TTM | TW$41.5 M |
| Profit Margin | 72.88% |
| Operating Margin | -858.53% |
| Quarterly Revenue Growth | -40.10% |
Stocks & Indices
Lumosa Therapeutics Co. Ltd has the following listings and related stock indices.
Stock: TWSE: 6535 wb_incandescent